Description

The purpose of this study is to find the largest safe dose of transforming growth factor-beta (TGFb) resistant latent membrane protein (LMP)-specific cytotoxic T cells, to learn what the side effects are and to see whether this therapy might help patients with Hodgkin disease, non-Hodgkin lymphoma and lymphoepithelioma.

Eligibility Criteria

Inclusion Criteria

Any patient, regardless of age or sex, with Epstein-Barr virus (EBV)-positive lymphoma, or lymphoepithelioma regardless of the histological subtype or EBV (associated)-T/natural killer (NK)-lymphoproliferative disorder (LPD) all confirmed on any tissue sample
* Primary refractory lymphoma or in second or subsequent relapse including after autologous or syngeneic stem cell transplant OR patients at a high risk for relapse defined as: (i) patients with primary refractory lymphoma or multiply relapsed lymphoma who are in remission but not eligible for autologous stem cell transplant (SCT) or (ii) patients with relapsed lymphoma after autologous SCT who are in remission but not eligible for allogeneic SCT (Group A) OR
* Any patient who has received an allogeneic SCT for EBV lymphoma or EBV (associated)-T/NK-LPD or lymphoepithelioma (Group B)

Patients with life expectancy >= 6 weeks from time of CTL infusion

Patients with a Karnofsky score of >= 50

If post allogeneic SCT must not have less than 50% donor chimerism in either peripheral blood or bone marrow